Angiotech secures Edwards' vascular graft business in $14m cash deal
This article was originally published in Clinica
Angiotech Pharmaceuticals is to acquire Edwards Lifesciences' Lifespan line of ePTFE (expanded polytetrafluoroethylene) vascular grafts for a cash sum of $14m. The transaction is expected to close in the fourth quarter of 2005.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.